Interações de Sorafenibe
Sorafenibe (Nexavar) tem 210 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 38; moderadas: 172; leves: 0; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.
Interações segundo a bula
Interações graves (38)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
- AxitinibeGrave
Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1) ] . (bula de Axitinibe, Advertências e precauções)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
- CarboplatinaGrave
• NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (bula de Sorafenibe, Contraindicações)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
- CisplatinaGrave
NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (bula de Sorafenibe, Advertências e precauções)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (bula de Sorafenibe, Advertências e precauções)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
Avoid concomitant use of NEXAVAR with neomycin. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
- PaclitaxelGrave
• NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (bula de Sorafenibe, Contraindicações)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (bula de Sorafenibe, Interações medicamentosas)
Interações moderadas (172)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (bula de Sorafenibe, Advertências e precauções)
Verifique Sorafenibe com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.
Abrir no verificadorNão é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.